Lewy body-related α-synucleinopathy in aging

Journal of Neuropathology and Experimental Neurology

Volumn 63, Issue 7, 2004, Pages 742-749

  Saito, Yuko ^a   Ruberu, Nyoka N ^a,b   Sawabe, Motoji ^c   Arai, Tomio ^c   Kazama, Hirohito ^c   Hosoi, Takayuki ^c   Yamanouchi, Hiroshi ^c   Murayama, Shigeo ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Tokyo Metropolitan Institute of Gerontology   (Japan)

Author keywords

Alzheimer disease; Apolipoprotein E; Dementia with Lewy body; Neurofibrillary tangle; Paraoxonase 1; Parkinson disease; Senile plaque

Indexed keywords

ALPHA SYNUCLEIN; APOLIPOPROTEIN E4; ARYLDIALKYLPHOSPHATASE;

ADULT; AGED; AGING; ALPHA SYNUCLEINOPATHY; ARTICLE; AUTOPSY; BRAIN DEGENERATION; CONTROLLED STUDY; DEMENTIA; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GENDER; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LEWY BODY; MALE; NEOCORTEX; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPATHY; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SENILE PLAQUE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

EID: 3042830032     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/63.7.742     Document Type: Article

References (28)

1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
2. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
3. Hasegawa K, Inoue K, Moriya K. An investigation of dementia rating scale for the elderly. Seishin Igaku 1974;16:965-69
4. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72
5. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
6. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-24
7. Yamaguchi H, Haga C, Hirai S, Nakazato Y, Kosaka K. Distinctive, rapid, and easy labeling of diffuse plaques in the Alzheimer brains by a new methenamine silver stain. Acta Neuropathol 1990;79:569-72
8. Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung 1971;19:1-8
9. Saito Y, Nakahara K, Yamanouchi H, Murayama S. Severe involvement of ambient gyrus in dementia with grains. J Neuropath Exp Neurol 2002;61:789-96
10. Saito Y, Kawashima A, Ruberu NN, et al. Accumulation of phosphorylated α-synuclein in aging human brain. J Neuropathol Exp Neurol 2003;62:644-54
11. Fujiwara H, Hasegawa M, Dohmae N, et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-64
12. Murayama S, Saito Y. Neuropathological diagnostic criteria for Alzheimer disease. Neuropathology (in press)
13. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1-S2
14. Jellinger KA. Dementia with grains (argyrophilic grain disease). Brain Pathol 1998;8:377-86
15. Jellinger KA, Bancher C. Senile dementia with tangles (tangle predominant form of senile dementia). Brain Pathol 1998;8:367-76
16. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60
17. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
18. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997;99:62-66
19. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-76
20. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:516-21
21. Suehiro T, Nakamura T, Inoue M, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000;150:295-98
22. Kosaka K, Iseki E. Diffuse Lewy body disease within the spectrum of Lewy body disease. In: Perry RH, McKeith IG, Perry EK, eds. Dementia with Lewy bodies. Cambridge: Cambridge University Press, 1996;238-47
23. Jellinger KA. α-Synuclein pathology in Parkinson's and Alzheimer's disease brain: Incidence and topographic distribution-a pilot study. Acta Neuropathol (Berl) 2003;106:191-201
24. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 2003;62:363-67
25. Wakabayashi K, Kakita A, Hayashi S, et al. Apolipoprotein E ε4 and allele and progression of cortical Lewy body pathology in Parkinson's disease. Acta Neuropathol (Berl) 1998;95:450-54
26. Lippa CF, Smith TW, Saunders AM, et al. Apolipoprotein E genotype and Lewy body disease. Neurology 1995;45:97-103
27. Harrington CR, Louwagie J, Rossau R, et al. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. Am J Pathol 1994;145:1472-84
28. Ruberu NN, Saito Y, Koyama S, et al. Alzheimer-type senile changes and ApoE genotyping. Neuropathology 2003;23:A42